{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mitchell M"],"funding":["National Institute of Allergy and Infectious Diseases","NCATS NIH HHS","NIAID NIH HHS"],"pagination":["241-247"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8926164"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(3)"],"pubmed_abstract":["<h4>Aim</h4>Among HIV-infected adults receiving efavirenz fixed-dose combination tablets, genotyping could guide efavirenz dose reduction but would require more pills.<h4>Methods</h4>We assessed willingness to dose reduce among 129 patients at an HIV primary care clinic in the southeastern USA.<h4>Results</h4>When told that switching from one pill to two or three pills \"might make you feel a little better\", 47% expressed definite or possible willingness. This decreased to 9% if there was \"a small chance it might not control your HIV as well\". Clinical variables were not associated with willingness.<h4>Conclusion</h4>Many patients receiving a fixed-dose combination tablet may be willing to take more pills in order to dose reduce, guided by genetic testing, but only if virologic control is not compromised."],"journal":["Personalized medicine"],"pubmed_title":["Patient willingness to undergo efavirenz dose reduction based on pharmacogenetic testing."],"pmcid":["PMC8926164"],"funding_grant_id":["UL1 000445","P30 AI110527","UL1 TR000445","R01 AI077505"],"pubmed_authors":["Wells C","Mitchell M","Zhang X","White J","Haas DW","Hughes J","Nash R"],"additional_accession":[]},"is_claimable":false,"name":"Patient willingness to undergo efavirenz dose reduction based on pharmacogenetic testing.","description":"<h4>Aim</h4>Among HIV-infected adults receiving efavirenz fixed-dose combination tablets, genotyping could guide efavirenz dose reduction but would require more pills.<h4>Methods</h4>We assessed willingness to dose reduce among 129 patients at an HIV primary care clinic in the southeastern USA.<h4>Results</h4>When told that switching from one pill to two or three pills \"might make you feel a little better\", 47% expressed definite or possible willingness. This decreased to 9% if there was \"a small chance it might not control your HIV as well\". Clinical variables were not associated with willingness.<h4>Conclusion</h4>Many patients receiving a fixed-dose combination tablet may be willing to take more pills in order to dose reduce, guided by genetic testing, but only if virologic control is not compromised.","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 May","modification":"2026-05-10T00:48:16.594Z","creation":"2025-04-05T17:35:43.488Z"},"accession":"S-EPMC8926164","cross_references":{"pubmed":["29767607"],"doi":["10.2217/pme-2015-0011"]}}